Lupin Q2 FY27 Results: Sales Grow 14% While Profitability Contracts
Lupin Ltd 路 Press Release 路 04 Nov 2026, 7:18 am
Lupin Q2 FY27 Results: Sales Grow 14% While Profitability Contracts Lupin reported consolidated sales of INR 77,855 Mn for Q2 FY27, up 14.0% YoY but down 5.3% QoQ. EBITDA declined 10.7% YoY to INR 21,712 Mn, with margins contracting 770 bps YoY to 27.9%, pressured by higher personnel and manufacturing costs. PAT dropped 22.2% YoY to INR 11,553 Mn. Geographically, U.S. sales rose 9.3% YoY to INR 30,202 Mn, India grew 14.7% to INR 23,836 Mn, and Other Developed Markets surged 45.7%. R&D investments reached INR 6,181 Mn (7.9% of sales). As of 30th Sep'26, net debt stood at INR -33,490 Mn.
Original exchange filing (PDF)
More announcements from Lupin Ltd
- Lupin Announces European Launch of Biosimilar Ranibizumab. 路 12 Nov 2026
- Transcript of Q2 FY2027 Earnings Conference Call. 路 07 Nov 2026
- Link of Audio recording of the Earnings Call-Q2 FY27. 路 05 Nov 2026
- Investor Presentation- Q2 FY2027 路 04 Nov 2026
- Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with .... 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Lupin Limited has submitted to the Exchange, the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
